Summary. Diabetes mellitus is a frequent transient or rare permanent complication of pregnancy. The role of autoimmune phenomena in this gestational form of diabetes is incompletely understood. We have examined sera from 312 pregnant women who had abnormal glucose tolerance (based on a screening examination during the second trimester) for the presence of islet cell surface antibodies or insulin autoantibodies. Fifty-eight of these women were lost to follow-up. Of the remaining subjects, 144 (57.1%) had gestational diabetes diagnosed by formal glucose tolerance testing and the others (42.9%) were normal. Sixty percent of the women with gestational diabetes eventually required insulin to control their blood glucose during pregnancy. One serum from the non-diabetic women was positive for insulin antibodies (0.9%); 8 of the sera from the patients with gestational diabetes were positive (5.6%). Subsequent analysis revealed that all nine of the women whose sera were positive for insulin autoantibodies had been treated with insulin previously. Islet cell surface antibodies were strongly correlated with gestational diabetes. Forty-five of 144 gestational diabetic sera were positive (31.3 %) whereas only 9 of 108 suspect control sera (8.3%) and 7 of 60 unknown sera (11.7%) were positive. These data suggest that a high percentage of pregnant women who screen positive for glucose intolerance have serological evidence of an autoimmune response against the pancreatic islets, in spite of the state of relative immune tolerance during pregnancy. These data suggest that autoimmune phenomena may play a role in gestational diabetes and that the presence of islet cell antibodies can predict insulin-requiring gestational diabetes.
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The hypothesis that autoimmunity plays a role in the pathogenesis of Type 1 (insulin-dependent) diabetes mellitus has been supported by many observations in both humans [1, 2] and in spontaneously diabetic rodents [3] [4] [5] . While it is well-known that the development of glucose intolerance during pregnancy (gestational diabetes) increases the risk of subsequently developing permanent diabetes to as high as 35% [6] [7] , the role of autoimmunity in the pathogenesis of gestational diabetes has not been extensively studied. The purpose of this study was to determine prospectively whether women who develop gestational diabetes manifested humoral markers of autoimmune diabetes, islet cell surface antibodies (ICSA) and insulin autoantibodies (IAA), and whether the presence of such markers was associated with the eventual need for insulin treatment during pregnancy.
Subjects and methods

Patients
All women attending the pre-natal clinic at Mount Sinai Medical Center during 1983-1984 were tested for the presence of glucose intolerance between weeks 18 and 28 of gestation. These women were predominantly Hispanic (65%) and Black (32%) and the majority were receiving public assistance. The screening test involved ingestion of 50 g of glucose orally with determination of serum glucose i h later. The screening was performed the first time the patient attended clinic and the women were not asked to fast prior to the test. All women with a positive screen according to the criteria then applied in the pre-natal clinic, i.e. a serum glucose greater than 8.3 mmol/l 1 h after the glucose ingestion were asked to return fasting in the early morning for a formal glucose tolerance test using 75 g of glucose orally. Some of these women did not return and hence their eventual diabetic status is unknown. Gestational diabetes was then diagnosed on the basis of the criteria of the American Diabetes Association [8] , if any two values exceeded the following: fasting serum glucose, 5.8 mmol/1; 1 h, 10.6 mmol/1; 2 h, 9.2 mmol/1; 3 h, 8.1 mmol/1. A majority of these women who had a positive screening test were found to meet the criteria for gestational diabetes (GD). Although the remaining women had a normal glucose tolerance test, as they had been abnormal in the screen for glucose intolerance they are therefore termed, "suspect control subjects". Those women with gestationat diabetes were then taught home blood glucose monitoring and were given diets restricted in simple carbohydrates, and providing sufficient calories to allow a weight gain of 20-30 pounds (9.1-13.6 kg) during gestation. If the blood glucose concentration could not be maintained within the acceptable range of the clinic at that time, i.e. fasting blood glucose 6.67 mmol/1 or below, postprandial blood glucose 10 mmol/1 or below, insulin treatment was initiated. It should be noted that these criteria have subsequently been made more stringent so that more of these women would now be treated with insulin.
Assays of pancreatic autoimmunity
The sera from patients who were abnormal during the screening blood glucose determination were saved and subsequently tested for the presence of ICSA and IAA. The results of these assays were obtained without knowledge of the clinical diagnosis and then the results were analysed after grouping according to the clinical status of each patient.
The presence of ICSA was determined by a complement-mediated cytotoxicity assay [9] using rat insulinoma cells (RIN 5F) as the target. Sera were positive if greater than 50% of the cells were killed. All sera were tested in at least two separate assays. Four sera from 160 normal blood donors were positive in this assay (2.5%). IAA were determined by a liquid phase displacement assay [10] using acid-charcoal stripped sera [11] and 1 BU of monoiodinated 125I-labelled human insulin (Amersham, Arlington Heights, Ill., USA). Duplicate samples of a 1:10 final dilution of each serum were incubated for 72 h at 4~ in the presence or absence of 4 btg (20 gg/ml) of human insulin (Squibb-Novo, Princeton, N J, USA) an amount demonstrated in preliminary testing to maximally displace labelled insulin from insulin-induced, anti-insulin antibodies. The difference in the counts in the presence and absence of the unlabelled insulin was determined and divided by the total counts from the I gU of radiolabelled insulin to calculate the absolute level of labelled insulin specifically bound be each whole serum. Sera from 160 normal blood donors were also determined yielding a mean + 1 SD of 0.07 +0.06 gU/ml. The normal range was then defined as the mean + 2 SD or 0.20 gU/ml or greater. No serum from any normal donor had an insulin autoantibody level outside of the normal range.
Statistical analysis
The proportion of sera positive for ICSA in each of the patient groups defined above were compared to the blood donor control subjects and to each other by Chi Square analysis. The levels of IAA were compared between the groups using Student's t-test. Differences were significant ifp < 0.05.
Results
During the period of this study, a total of 312 women who presented to the pre-natal clinic had a positive screening test for glucose intolerance. This represents approximately 23% of those tested. Fifty-eight (18.6%) of these women did not return for their glucose tolerance tests and were subsequently lost to follow-up. This group whose subsequent glucose tolerance remained unknown (UNK) was separated from the others for comparison. Of the 254 women who had a glucose tolerance test, 144 (57.1%) met the criteria for gestational diabetes (GD) and treatment was begun. The ethnic distribution of these women, 89 Hispanic (62%) 49 Black (34%) did not vary significantly from the group as a whole (Chi Square, p > 0.05). Eventually, 86 of these women (59.7%) required insulin during their pregnancy. The other women with gestational diabetes were managed on diet alone. 110pregnant women with an abnormal screening test proved to be normal on the single formal oral glucose tolerance testing and were designated the suspect control group (SC). 
Islet cell surface antibodies
The rate of positivity for ICSA in the three patient groups is presented in Table 1 . As can be appreciated, the presence of positive ICSA was strongly associated with the presence of gestational diabetes. Among the GD group, 45 of 144 (31.3%) were positive for ICSA vs 9 of 110 SC (8.3%, p < 0.00001) and 7 of 60 UNK patients (11.7% ,p < 0.01). If all of the UNK are considered as not having diabetes, ICSA positivity was more strongly associated with GD,p < 0.00001. Within the GD group, those that required insulin treatment had a significantly higher prevalence of ICSA (41 of 86) than those that were treated with diet alone (4 of 58,p < 0.00001, relative risk for needing insulin --12.3). It must be noted that all of these groups had a prevalence of ICSA significantlygreater than 110 normal blood donor control subjects (1.8%, vs UNK, p < 0.02; Vs SC, p < 0.05; vs GD,p < 0.00001) although the comparison with the SC group barely reached statistical significance.
Insulin autoantibodies
The levels of IAA in these patients are presented in Figure 1 . None of the UNK patients were IAA positive. One serum (0.9%) from a SC patient was positive as were sera from eight GD patients (5.6%). Subsequent examination of the medical records of these patients revealed that all nine of these individuals had been treated with insulin during a previous pregnancy. Thus, it is impossible to verify that the insulin antibodies detected were autoimmune, but rather, it is likely that they had been generated in response to the previous insulin treatment. When the results from the patients who had been treated with insulin were excluded, there was no difference in insulin binding in any of these groups compared to the blood donor controls, UNK = 0.06 + 0.006 BU/ml, n = 58; SC = 0.07 + 0.004, n = 109; GD = 0.07 + 0.004, n = 136,p > 0.05.
Discussion
The American Diabetes Association has published criteria for the diagnosis of gestational diabetes which identify pregnancies at risk for both maternal and fetal complica- The three groups of patients are identified: UNK = the women lost to follow-up whose eventual glucose tolerance is unknown; SC = suspect controls who had a normal glucose tolerance test after an abnormal screening examination; and GD = the subjects who had gestational diabetes on formal glucose tolerance testing. The horizontal dashed line represents the mean + 2 SD for normal blood donors. One serum in the SC group and eight sera in the GD group were above the normal range, however, a chart review revealed that all nine of these subjects had been treated with insulin for gestational diabetes during a previous pregnancy. After exclusion of these data, there was no difference in insulin binding among any of these groups or between the normal blood donors and any of these groups tions [8] . There has been a downward trend in the acceptable upper limit of normal blood glucose concentration during pregnancy, although there is still disagreement as to the absolute limits that should be imposed [12] [13] [14] [15] [16] and, especially, to the criteria for screening pregnant women for glucose intolerance and to the test that should be employed [17] [18] . The criteria for screening in our institution and for the introduction of insulin therapy in gestational diabetes have been lowered since the present study was conducted using sera obtained in 1983-1984. Since we [11] and others [19] have reported that the presence of IAA at the onset of Type i diabetes declines with increasing age, it was not surprising that none of the pregnant subjects in our study who had not previously taken exogenous insulin were positive for IAA. Vardi et al. [10] have reported far greater sensitivity in their insulin autoantibody assay than the one used in this study so it is possible that low but detectable levels of insulin antibodies were present in some of the patients. Subsequent to these studies, we have modified our insulin autoantibody to achieve sensitivity comparable to that reported by Vardi et al. In the most recent Immunology of Diabetes Proficiency Test, this assay was rated as 100% sensitive and specific. Retesting of these sera with this more sensitive assay revealed no other serum positive for IAA.
The determination of ICSA in samples obtained at the time of preliminary screening proved to be very predictive in identifying those patients who would eventually develop gestational diabetes and, most importantly, those who would require insulin treatment. It remains surprising that so many patients with gestational diabetes should have detectable islet cell antibodies. While it has been shown that gestational diabetes markedly increases the 509 subsequent risk for permanent diabetes [6, 7] , the majority of such patients have been expected to manifest the Type 2 (non-insulin-dependent) form of the disease. However, many of the women who were ICSA positive required insulin for adequate glucose control during their pregnancy, indicating some level of insulin deficiency at least under the stress of pregnancy. Further follow-up is required and is underway to determine the eventual rate of diabetes in these women and to ascertain in this large group whether positivity for ICSA is equally predictive of permanent insulin-requiring diabetes as we have previously reported in a much smaller group [20] .
Although this is, to our knowledge the first report of a prospective assessment of markers of pancreatic autoimmunity in pregnancy prior to the diagnosis of GD, we and others have previously reported the measurement of islet cell antibodies during pregnancy in small numbers of patients already diagnosed with GD. In our first study [20] , the incidence of ICA, measured by the fluoresceinlabelled second antibody method on sections of blood type 0 human pancreas, was similar to that in the present study, 28 of 80, 35%. Subsequently, we reported that the HLA types of women with gestational diabetes did not differ from a similar population without diabetes during pregnancy [21] , but, in that study, 20 of 52 sera (38.5%) from women with GD were positive for ICA and a very high association was found between ICA positivity and expression of the HLA types associated with Type 1 diabetes, specifically DR3 and DR4.
Using a commercial assay, Freinkel et al.
[22] were unable to demonstrate an increase in islet cell antibodies in women with only minimal impairment of glucose tolerance during pregnancy, but they did report an increasing percentage of gestational diabetic women who were antibody positive as the level of glucose impairment increased, to as high as 18.4%. Unfortunately, these authors did not separate their patients as to whether they required insulin or not, so no direct comparison with the present data is possible. In contrast, another group recently examined sera from 187 women with gestational diabetes within 7 days after delivery for the presence of ICA in using a protein A-monoclonal antibody method. Only three of these women (1.6%) were found to be positive with this assay and the ICA positive women had a higher postpartum fasting glucose and a lower first-phase insulin response to intravenous glucose than did women who were ICA negative.
Resolution of the continuing debate as to the advantages and disadvantages of each of the different islet cell antibody assays is beyond the scope of this report. It is clear that the different assays are detecting antibodies directed against different Beta-cell antigens. While it is unlikely that all of the women who were ICSA positive during their pregnancies complicated by gestational diabetes will develop Type 1 diabetes, the ICSA assay we used in this study was highly predictive in identifying those women who were likely to require insulin to maintain glucose homeostasis during pregnancy. Clearly, the decision to institute insulin treatment during pregnancy must rest on established clinical guidelines. However, the fact that positivity in the ICSA assay was able to identify women likely to require insulin, suggests that the assay detects some humoral response that may reflect anti-Beta cell autoimmunity or may itself temporarily reduce insulin secretion during gestation. Further characterization of such a putative humoral response during pregnancy deserves further investigation.
